CAESAREA, Israel, May 21, 2019 /PRNewswire/ -- DarioHealth Corp.
(Nasdaq: DRIO) ("DarioHealth" or the "Company"), a global
digital therapeutics innovator, today announced that it intends to
offer and sell shares of common stock (or pre-funded warrants in
lieu thereof) in an underwritten public offering. The proposed
offering is subject to market and other conditions, as well as
customary closing conditions, and there can be no assurance as to
whether or when the proposed offering may be completed, or as to
the actual size or terms of the offering.
Craig-Hallum Capital Group is acting as sole managing
underwriter for the offering.
DarioHealth intends to use the net proceeds of the offering for
commercialization efforts for its products, such as increased
marketing or production expenses, and for general working capital
purposes.
The securities are being offered pursuant to an effective shelf
registration statement on Form S-3 (File No. 333-212644) that was
previously filed with the Securities and Exchange Commission (the
"SEC"), and was declared effective on August
3, 2016. The securities may be offered only by means of a
prospectus. A preliminary prospectus supplement and accompanying
prospectus relating to the offering will be filed with the SEC and
will be available on the SEC's website at www.sec.gov. Copies of
the preliminary prospectus supplement and accompanying prospectus
related to the offering may also be obtained from Craig-Hallum
Capital Group LLC at 222 South Ninth Street, Suite 350,
Minneapolis, Minnesota 55402,
Attention: Equity Capital Markets, by telephone at 612-334-6300, or
by email at prospectus@chlm.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or other jurisdiction in which such
an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or other jurisdiction.
About DarioHealth Corp
DarioHealth Corp. (Nasdaq: DRIO) is a leading global Digital
Therapeutics (DTx) company revolutionizing the way people manage
their health across the chronic condition spectrum. By delivering
evidence-based interventions that are driven by data, high quality
software and coaching, we developed a novel approach that empowers
individuals to adjust their lifestyle in a personalized way. Our
Cross Functional Team operates at the intersection of life
sciences, behavioral science and software technology to deliver
highly engaging therapeutic interventions. Already one of the
highest rated diabetes solutions, its user-centric approach is
loved by tens of thousands consumers around the globe. DarioHealth
is rapidly moving into new chronic conditions and geographic
markets.
Cautionary Note Regarding Forward-Looking Statements:
This news release and the statements of
representatives and partners of DarioHealth Corp. related thereto
contain or may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Statements that are not statements of historical fact may be deemed
to be forward-looking statements. Without limiting the generality
of the foregoing, words such as "plan," "project," "potential,"
"seek," "may," "will," "expect," "believe," "anticipate," "intend,"
"could," "estimate" or "continue" are intended to identify
forward-looking statements. For example, the Company is using
forward-looking statements in this press release when the Company
discusses the expected offering and its intended use of
proceeds. Readers are cautioned that certain important factors
may affect the Company's actual results and could cause such
results to differ materially from any forward-looking statements
that may be made in this news release. Factors that may affect the
Company's results include, but are not limited to, regulatory
approvals, product demand, market acceptance, impact of competitive
products and prices, product development, commercialization or
technological difficulties, the success or failure of negotiations
and trade, legal, social and economic risks, and the risks
associated with the adequacy of existing cash resources. Additional
factors that could cause or contribute to differences between the
Company's actual results and forward-looking statements include,
but are not limited to, those risks discussed in the Company's
filings with the U.S. Securities and Exchange Commission. Readers
are cautioned that actual results (including, without limitation,
the timing for and results of the Company's commercial and
regulatory plans for Dario as described herein) may differ
significantly from those set forth in the forward-looking
statements. The Company undertakes no obligation to publicly update
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
applicable law.
DarioHealth Contact:
Joao
Mendes-Roter
VP Marketing
joao@mydario.com
+1-347-767-4220
View original content to download
multimedia:http://www.prnewswire.com/news-releases/dariohealth-corp-announces-commencement-of-public-offering-of-common-stock-300854583.html
SOURCE DarioHealth Corp.